Effect of Crocin and Crocetin Compared to Cyclophosphamide on the Expression Level of miRNA-16-1 in a B Cell Transformed with EBV Virus Cell Line.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Sep 2024
Historique:
received: 21 04 2024
medline: 29 9 2024
pubmed: 29 9 2024
entrez: 29 9 2024
Statut: epublish

Résumé

Crocin and Crocetin are compounds that have shown promising therapeutic potentials in various medical contexts. To date, the effect of crocin and crocetin on the expression level of miRNA-16-1 in Epstein Barr Virus (EBV)-induced lymphoma has not been investigated. This research delved into a comparative analysis of the cytotoxic effects of crocin and crocetin compared to cyclophosphamide, the main drug used in the treatment of lymphoma and PTLD, on B-cell lymphoma infected with EBV (cell line CO 88BV59-1). Additionally, the study examines the changes in miRNA-16-1 expression following these treatments in this cell line. CO 88BV59-1 LCL cells were treated with crocin, crocetin (0.2 to 200 μM), and cyclophosphamide (0.05 to 50 μM) for 72 hours. Cell viability and apoptosis were assessed using resazurin and Annexin V/PI techniques, respectively. Additionally, the expression of miRNA-16-1-3p and miRNA-16-1-5p was determined using the Real-Time PCR method. The data were analyzed using one-way analysis of variance (ANOVA) with Tukey's multiple comparisons post-hoc test. Crocin and crocetin inhibited the proliferation and apoptosis caused by EBV-infected cells in a dose- and time-dependent manner (P<0.05). The expression levels of miRNA-16-1-3p and miRNA-16-1-5p remained unchanged in cells treated with crocin and crocetin. The study found that the cytotoxic effect of Crocin, Crocetin, and Cyclophosphamide on CO 88BV59-1 LCL is independent of the expression level of miRNA-16-1. The results showed a reduction in cell survival and an increase in cell death.

Identifiants

pubmed: 39342597
doi: 10.31557/APJCP.2024.25.9.3179
pii:
doi:

Substances chimiques

MicroRNAs 0
Carotenoids 36-88-4
Vitamin A 11103-57-4
trans-sodium crocetinate 0
crocin 877GWI46C2
Cyclophosphamide 8N3DW7272P
MIRN16 microRNA, human 0

Types de publication

Journal Article Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

3179-3185

Auteurs

Malihe Moradzadeh (M)

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Mohammad Kargar (M)

Department of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.

Saeideh Erfanian (S)

Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran.

Mohammad Reza Haghshenas (MR)

Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Mohammad Hojjat-Farsangi (M)

Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.

Karamatollah Rahmanian (K)

Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran.

Abdolreza Sotoodeh Jahromi (A)

Department of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH